Replication-competent Adenovirus-mediated Double Suicide Gene Therapy With Fractionated Stereotactic Radiosurgery in Progressive Glioblastoma: A Phase One Trial
Tobias Walbert1, Ian Lee2, James M. Snyder2, Mira M. Shah2, Salim M. Siddiqui2, Adam M. Robin2, Stephen L. Brown2, Benjamin Movsas2, Farzan Siddiqui2, Shyam Nyati2
1Henry Ford Hospital Detroit, 2Henry Ford Health Detroit
Objective:
We conducted a single site, nonrandomized, dose-escalation phase 1 trial of a replication competent novel adenovirus harboring two suicide genes (HSV-TK, yCD) and ADP expression cassette for treatment of adult patients with recurrent Glioblastoma (rGBM) undergoing repeat craniotomy followed by fractionated stereotactic radiosurgery (fSRS). The primary endpoints of this dose escalation study were to establish the maximum tolerated dose (MTD) and safety up to Day 90. Secondary endpoints were virus persistence, level of immunological cytokines, Quality of Life and overall survival (mOS).
Background:
Recurrent GBM is marked by short median survival and there is no standard treatment.
Design/Methods:
After craniotomy and maximal resection, the ADP adenovirus was injected into remaining tumor tissue and/or the adjacent brain tissue around the resection cavity. Patients received prodrug therapy consisting of 4 days of 5-fluorocytosine (150 mg/kg/day, orally) and valganciclovir (1800 mg/daily) for 13 days. 6-7 days post-surgery, patients received 4 doses of fSRS (32Gy total). Toxicity, virus persistence, immunological cytokines, and immune cell activation were measured up to day 30. The study followed a 3+3 design, with 3 doses of viral particles (1x1011, 3x1011, 1x1012).
Results:
A total of 16 patients with rGBM, IDH1wt, were enrolled. One patient in cohort 1 had a seizure and another patient in cohort 3 had focal weakness, the trial was extended by 6 patients. The Ad5-yCD/mutTKSR39rep-ADP adenovirus plus fSRS was safe and well tolerated in rGBM. MTD was not reached. The majority of adverse events were grade 1 or 2. Grade 3 adverse events included one event of headache, nausea, vomiting, hyponatremia, seizure, weakness and were not attributed to study treatment. No grade 4 or 5 events were observed.
Conclusions:
Treatment was overall well tolerated. Patients on Ad5-yCD/mutTKSR39rep-ADP gene therapy with combined fSRS had an mOS of 12.3 months. Complete results will be reported.
Disclaimer: Abstracts were not reviewed by Neurology® and do not reflect the views of Neurology® editors or staff.